CA2828959A1 - Methods and compositions for predicting response to eribulin - Google Patents

Methods and compositions for predicting response to eribulin Download PDF

Info

Publication number
CA2828959A1
CA2828959A1 CA2828959A CA2828959A CA2828959A1 CA 2828959 A1 CA2828959 A1 CA 2828959A1 CA 2828959 A CA2828959 A CA 2828959A CA 2828959 A CA2828959 A CA 2828959A CA 2828959 A1 CA2828959 A1 CA 2828959A1
Authority
CA
Canada
Prior art keywords
expression
biomarker
eribulin
subject
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2828959A
Other languages
English (en)
French (fr)
Inventor
Sergei I. Agoulnik
Michael Chapman Byrne
Bruce A. Littlefield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of CA2828959A1 publication Critical patent/CA2828959A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
CA2828959A 2011-03-18 2012-03-16 Methods and compositions for predicting response to eribulin Abandoned CA2828959A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161454426P 2011-03-18 2011-03-18
US61/454,426 2011-03-18
PCT/US2012/029479 WO2012129100A1 (en) 2011-03-18 2012-03-16 Methods and compositions for predicting response to eribulin

Publications (1)

Publication Number Publication Date
CA2828959A1 true CA2828959A1 (en) 2012-09-27

Family

ID=45879070

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2828959A Abandoned CA2828959A1 (en) 2011-03-18 2012-03-16 Methods and compositions for predicting response to eribulin

Country Status (8)

Country Link
US (1) US9637795B2 (https=)
EP (1) EP2686441B1 (https=)
JP (3) JP2014509515A (https=)
CN (1) CN103562406B (https=)
CA (1) CA2828959A1 (https=)
ES (1) ES2731653T3 (https=)
SG (2) SG193489A1 (https=)
WO (1) WO2012129100A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369008B (zh) 2009-03-30 2014-10-29 卫材R&D管理有限公司 脂质体组合物
RU2689977C2 (ru) * 2012-12-04 2019-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина для лечения рака молочной железы
BR112015029386B1 (pt) * 2013-06-26 2023-11-14 Eisai R&D Management Co., Ltd. Uso de eribulina e lenvatinibe como terapia de combinação e kit
US20170100367A1 (en) * 2014-05-28 2017-04-13 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of cancer
WO2015184145A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
AU2016226157B2 (en) * 2015-03-04 2022-01-27 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
US10669545B2 (en) 2015-05-01 2020-06-02 Japan Science And Technology Agency Tumor cell malignant transformation suppressor and anti-tumor agent
PE20231050A1 (es) 2016-03-02 2023-07-11 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2020179712A1 (en) * 2019-03-01 2020-09-10 Eisai R&D Management Co., Ltd. Methods for predicting tumor response to eribulin
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN113174427B (zh) * 2021-04-29 2023-02-28 遵义医科大学 基于DNA分子检测ERGIC3 mRNA的方法
CN113512733B (zh) * 2021-05-13 2022-07-26 浙江工业大学 一种电化学nhk反应合成艾日布林中间体的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5075216A (en) 1988-09-23 1991-12-24 Cetus Corporation Methods for dna sequencing with thermus aquaticus dna polymerase
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
CA2124087C (en) 1991-11-22 2002-10-01 James L. Winkler Combinatorial strategies for polymer synthesis
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
JP4454151B2 (ja) 1998-06-17 2010-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 大環状類似体及びそれらの使用並びに調製方法
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
WO2005032347A2 (en) * 2003-10-01 2005-04-14 The Ohio State University Research Foundation Determining the chemosensitivity of cells to cytotoxic agents
US20060154312A1 (en) * 2004-12-09 2006-07-13 Sergei Agoulnik Tubulin isotype screening in cancer therapy using halichondrin B analogs
TW201132813A (en) * 2010-03-03 2011-10-01 Koo Foundation Sun Yat Sen Cancer Ct Methods for classifying and treating breast cancers

Also Published As

Publication number Publication date
US20140235707A1 (en) 2014-08-21
CN103562406A (zh) 2014-02-05
ES2731653T3 (es) 2019-11-18
US9637795B2 (en) 2017-05-02
JP2019150027A (ja) 2019-09-12
WO2012129100A1 (en) 2012-09-27
SG193489A1 (en) 2013-10-30
EP2686441B1 (en) 2019-05-08
JP2017148049A (ja) 2017-08-31
JP6612280B2 (ja) 2019-11-27
EP2686441A1 (en) 2014-01-22
JP2014509515A (ja) 2014-04-21
SG10201602147YA (en) 2016-05-30
CN103562406B (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
EP2686441B1 (en) Methods and uses for predicting response to eribulin
EP3458604B1 (en) Method for determining sensitivity to a cdk4/6 inhibitor
US20130042333A1 (en) Markers for cancer prognosis and therapy and methods of use
KR101357032B1 (ko) 도세탁셀에 대한 내성 또는 감수성을 측정하는 방법
CA2844793A1 (en) Methods and compositions for the treatment and diagnosis of cancer
EP2744917A2 (en) Methods and compositions for the treatment and diagnosis of breast cancer
US9274117B2 (en) Use of SIRT7 as novel cancer therapy target and method for treating cancer using the same
WO2017069710A1 (en) Composition for modulating irak1
WO2020082037A1 (en) Methods for treating a subtype of small cell lung cancer
KR102238258B1 (ko) 간암 진단을 위한 신규 바이오마커 및 이를 이용한 치료 방법
AU2008357875A1 (en) Interferon Epsilon (IFNE1) as a marker for targeted cancer therapy
CN112462072B (zh) 一种tmub1蛋白在制备肿瘤免疫抑制分子检测剂中的应用
US20250002918A1 (en) Compositions and methods for treatment of mic60 depleted cancers and metastasis
AU2015264870A1 (en) Method for predicting and detecting tumor metastasis
KR102431271B1 (ko) 항암제 반응성 예측용 바이오마커 및 이의 용도
KR101150410B1 (ko) 간암 진단용 마커로서의 ｓ100ｐ의 용도
CN121874343A (zh) Rab26作为骨肉瘤的预后评估标志物和治疗靶点的应用
KR20230077936A (ko) 구강암의 시스플라틴 내성 예측용 바이오마커 및 이의 용도
EP3231875A1 (en) Prognostic biomarker for cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170221

FZDE Discontinued

Effective date: 20220609